Leveraging proprietary, high-efficiency gene-editing technologies, Biocytogen is a global leader in animal and cell model generation for preclinical research. Through BioMice?, we offer thousands of off-the-shelf drug-targeted humanized models, providing ready-to-use solutions for drug efficacy, safety, and mechanistic studies.
Beyond model generation, Biocytogen accelerates global drug discovery with comprehensive preclinical pharmacology and gene-editing services, driving breakthroughs in oncology, immunology, and beyond.
Leveraging its cutting-edge gene-editing expertise, Biocytogen has developed the proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE?) technology. Based on this innovative technique, Biocytogen employs a large-fragment in situ replacement strategy to seamlessly substitute human antibody gene sequences while preserving the mouse Fc region. This ensures the production of fully human antibodies while supporting normal immune system development, laying the foundation of Biocytogen's RenMice? antibody discovery platforms.
The RenMice? family—featuring RenMab?, RenLite?, RenNano?, RenTCRmimic?, and RenMice? KO—offers unparalleled versatility in antibody discovery:
Connect with Biocytogen to advance your drug discoveries together
Biocytogen partners with global companies to accelerate drug discovery and development. Our integrated platforms—including fully human antibody discovery, target-humanized models, preclinical pharmacology, and custom gene-editing—streamline the translation of promising biological insights into breakthrough therapies.
our featured partners
